Inclusion Criteria:  Age 18-60, no gender limitation HBsAg is positive for more than 6 months Hepatitis B e antigen(HBeAg) is negative and anti-HBe is positive Serum HBV DNA is less than 2000 IU/mL Alanine aminotransferase(ALT) and/or Aspartate aminotransferase(AST) is normal No antiviral durg (including nucleos(t)ide analogue and interferon) was used before enrollment Good compliance and voluntarily signed informed consent  Exclusion Criteria:  Allergic to pegylated interferon α-2b Any indication of liver cirrhosis Coinfection with hepatitis A virus(HAV), hepatitis C virus(HCV), hepatitis D virus(HDV), hepatitis E virus(HEV) or human immunodeficiency virus(HIV) Combined with other liver diseases (including drug-related, alcoholic, autoimmune, genetic metabolic liver diseases, etc.) There are serious lesions in the important organs, such as heart, lung, kidney, brain and fundus Patients with autoimmune diseases, unstable diabetes or thyroid diseases(hyperthyroidism or hypothyroidism) Confirmed or suspected liver cancer or other malignant tumors Patients after or preparing for organ transplantation Peripheral blood white blood cell count < 3.5×109/L and/or platelet count < 80×109/L Under immunosuppressant treatment Pregnant or planned pregnancy in a short term or lactation patients Alcohol abuse (average alcohol intake is more than 40 g/d in males or 20g/d in women) or drug addicts Present or past history of mental or psychological diseases Other conditions that the investigators deem inappropriate for the study.